Coriolis Pharma Adds Analytical Ultracentrifugation to Its Service Offerings

Coriolis Pharma, a globally operating service provider for drug product development, analytics and manufacturing support, has introduced Analytical Ultracentrifugation (AUC) under GMP, thereby meeting the increasing demand in the pharmaceutical and biotech industry and expanding its existing portfolio of GMP methods for the development of high-quality drug products.
 
AUC is recognized as a powerful technique for the detailed study of macromolecules, including proteins, nucleic acids, viral vectors, and nanoparticles. According to Coriolis, its ability to provide precise information on aggregation, molecule size, shape and interactions has made it indispensable in the field of biophysical characterization.
 
“Coriolis has been a world leading specialist for biopharmaceutical method development and testing by using AUC for almost a decade, featuring all available combinations of state-of-the-art AUC hard- and software,” said Dr. Frank Schaubhut, Head of Operations at Coriolis Pharma. “We’re proud to take our expertise to the next quality level with introducing this service under GMP.”
 
From the early development to post-market monitoring: AUC has proven its versatility in the various phases of drug development: Formulation development, quality control, comparability studies or post-marketing surveillance. It is therefore an important addition to Coriolis’ range of phase-appropriate analytical services under GMP, which also includes method development and validation, compendial method verification, release testing, tech transfer support, and stability testing.